A comparative study of neurobehavioral changes induced by rotenone through oral and intraperitoneal administration
Article Sidebar
-
Parkinson’s disease, Rotenone, intraperitoneal and oral toxicity, Wistar rats, neurobehavioral studies
Abstract
Parkinson’s disease is one of the major neurological disorders seen worldwide and associated with many motor and nonmotor symptoms. Rotenone-induced motor and behavior impairments could involve the gut-brain axis which is emphasized in several recent works. To explore how oral and intraperitoneal rotenone toxicity impacts neurobehavioral alterations in Wistar rats. The effect of intraperitoneal (3 mg/kg body weight 21 days) and oral (50 mg/kg body weight for 28 days) rotenone toxicity in male Wistar rats on various neurobehavioral parameters viz., rotarod, actophotometer, rearing behavior and elevated plus maze was comparatively studied. The neurobehavioral studies such as the Rota-rod test, rearing behavior, Elevated plus maze (EPM), and Actophotometer were performed by following standard published protocols and by utilizing the facilities available at the Institution. Kruskal-Wallis one- way ANOVA on ranks with Student-Newman-Keul’s multiple comparisons was used. It was found that both oral and intraperitoneal rotenone treatments had a significant impact on neurobehavioral parameters when compared to their respective controls. Although there were few differences observed in the study set behavioral parameters between intraperitoneal and oral rotenone treatments, it was not significant. The study findings suggest that neurobehavioral alterations caused by oral or intraperitoneal rotenone toxicity are found to be significant. The fact that oral rotenone toxicity has gut-brain axis- related problems can also have a role in PD-related motor/movement and anxiety behavior dysfunctions.
Full text article
References
D J Moore, A B West, V L Dawson, and T M Dawson. Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci, 28:57–87, 2005.
J Bové, D Prou, C Perier, and S Przedborski. Toxin-induced models of Parkinson’s disease. NeuroRx, 2(3):484–494, 2005.
M G Tansey and M S Goldberg. Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis, 37(3):510–518, 2010.
J T Greenamyre, J R Cannon, R Drolet, and P G Mastroberardino. Lessons from the rotenone model of Parkinson’s disease. Trends Pharmacol Sci, 31(4):141–143, 2010.
C Freire and S Koifman. Pesticide exposure and Parkinson’s disease: epidemiological evidence of association. Neurotoxicology, 33(5):947– 971, 2012.
Y Bogdanova and A Cronin-Golomb. Neurocognitive correlates of apathy and anxiety in Parkinson’s disease. Parkinsons Dis, 2012, 2012. Article ID: 793076.
O Kano, K Ikeda, D Cridebring, T Takazawa, Y Yoshii, and Y Iwasaki. Neurobiology of depression and anxiety in Parkinson’s disease. Parkinson’s Dis, 2011, 2011. Article ID: 143547.
L H Morais, D B Hara, M A Bicca, A Poli, and R N Takahashi. Early signs of colonic inflammation, intestinal dysfunction, and olfactory impairments in the rotenone-induced mouse model of Parkinson’s disease. Behav Pharmacol, 29(2-3 special issue):199–210, 2018.
L Klingelhoefer and H Reichmann. Pathogenesis of Parkinson’s disease–the gut-brain axis and environmental factors. Nat Rev Neurol, 11(11):625–661, 2015.
C Pellegrini, L Antonioli, R Colucci, V Ballabeni, E Barocelli, N Bernardini, C Blandizzi, and M Fornai. Gastric motor dysfunctions in Parkinson’s disease: Current preclinical evidence. Parkinsonism Relat Disord, 21(12):1407–1414, 2015.
F Pan-Montojo, O Anichtchik, Y Dening, L Knels, S Pursche, R Jung, S Jackson, G Gille, M G Spillantini, H Reichmann, and R H Funk. Progression of Parkinson’s disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One, 5(1):8762–8762, 2010.
H B Dodiya, C B Forsyth, R M Voigt, P A Engen, J Patel, M Shaikh, S J Green, A Naqib, A Roy, J H Kordower, K Pahan, K M Shannon, and A Keshavarzian. Chronic stress-induced gut dysfunction exacerbates Parkinson’s disease phenotype and pathology in a rotenone- induced mouse model of Parkinson’s disease. Neurobiol Dis, 2018. Article ID: 30768.
F J Pan-Montojo and R H Funk. Oral administration of rotenone using a gavage and image analysis of alpha-synuclein inclusions in the enteric nervous system. J Vis Exp, (44):2123– 2123, 2010.
J R Cannon, V Tapias, H M Na, A S Honick, R E Drolet, and J T Greenamyre. A highly reproducible rotenone model of Parkinson’s disease. Neurobiol Dis, 34(2):279–290, 2009.
U A Bhosale, R Yegnanarayan, P D Pophale, M R Zambare, and R S Somani. Study of central nervous system depressant and behavioral activity of an ethanol extract of Achyranthes aspera (Agadha) in different animal models. Int J Appl Basic Med Res, 1(2):1048–1048, 2011.
Y J Ho, J Eichendorff, and R K Schwating. Individual response profiles of male Wistar rats in animal models for anxiety and depression. Behv Brain Res, 136(1):1–12, 2002.
S Pellow and S E File. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav, 24(3):525– 529, 1986.
S A Zaitone, D M Abo-Elmatty, and S M Elshazly. Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats. Indian J Pharmacol, 44(6):774–779, 2012.
S M Fleming, C Zhu, P O Fernagut, A Mehta, C D Dicarlo, R L Seaman, and M F Chesselet. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp Neurol, 187(2):418–429, 2004.
M Sonia Angeline, P Chaterjee, K Anand, R K Ambasta, and P Kumar. Rotenone-induced Parkinsonism elicits behavioral impairments and differential expression of parkin, heat shock proteins and caspases in the rat. Neuroscience, 220:291–301, 2012.
S Kavuri, S Sivanesan, M D Howell, R Vijayaraghavan, J Rajadas, and World Journal of Neuroscience. Studies on Parkinson’s- Disease-Linked Genes, Brain Urea Levels and Histopathology in Rotenone Induced Parkinson’s Disease Rat Model. 10(4):216–234, 2020.
F L Campos, M M Carvalho, A C Cristovão, G Je, G Baltazar, A J Salgado, Y S Kim, and N Sousa. Rodent models of Parkinson’s disease: beyond the motor symptomatology. Front Behav Neurosci, 7:175, 2013.
V Venkateshgobi, S Rajasankar, Wms Johnson, K Prabu, and M Ramkumar. Neuro protective Effect of Agaricus Blazei Extract Against Rotenone-Induced Motor and Non-motor Symptoms in Experimental Model of Parkinson’s Disease. Int J Nutr Pharmacol Neurol Dis, 8(2):59–65, 2018.
D Litteljohn, E N Mangano, and S Hayley. Cyclooxygenase-2 deficiency modifies the neurochemical effects, motor impairment and comorbid anxiety provoked by paraquat administration in mice. Eur J Neurosci, 28(4):707– 716, 2008.
D Litteljohn, E Mangano, N Shukla, and S Hayley. Interferon-gamma deficiency modifies the motor and co-morbid behavioral pathology and neurochemical changes provoked by the pesticide paraquat. Neuroscience, 164(4):1894–1906, 2009.
A Czerniczyniec, A G Karadayian, J Bustamante, R A Cutrera, and S Lores-Arnaiz. Paraquat induces behavioral changes and cortical and striatal mitochondrial dysfunction. Free Radic Biol Med, 51(7):1428–1436, 2011.
D K Khatri and A R Juvekar. Neuroprotective effect of curcumin as evinced by abrogation of rotenone-induced motor deficits, oxidative and mitochondrial dysfunctions in mouse model of Parkinson’s disease. Pharmacol Biochem Behav, 150-151:39–47, 2016.
Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Article Details
